Abstract:Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) have significantly prolonged the survival of advanced/metastatic patients with lung cancer. However, only a small proportion of patients can benefit from ICIs, and clinical management of the treatment process remains challenging. Glycosylation has added a new dimension to advance our understanding of tumor immunity and immunotherapy. To systematically characterize anti-PD-1/PD-L1 immunotherapy-related changes in serum glycoproteins, a series of serum samples from 12 patients with metastatic lung squamous cell carcinoma (SCC) and lung adenocarcinoma (ADC), collected before and during ICIs treatment, are firstly analyzed with mass-spectrometry-based label-free quantification method. Second, a stratification analysis is performed among anti-PD-1/PD-L1 responders and non-responders, with serum levels of glycopeptides correlated with treatment response. In addition, in an independent validation cohort, a large-scale site-specific profiling strategy based on chemical labeling is employed to confirm the unusual characteristics of IgG N-glycosylation associated with anti-PD-1/PD-L1 treatment. Unbiased label-free quantitative glycoproteomics reveals serum levels' alterations related to anti-PD-1/PD-L1 treatment in 27 out of 337 quantified glycopeptides. The intact glycopeptide EEQFN 177STYR (H3N4) corresponding to IgG4 is significantly increased during anti-PD-1/PD-L1 treatment (FC=2.65, P=0.0083) and has the highest increase in anti-PD-1/PD-L1 responders (FC=5.84, P=0.0190). Quantitative glycoproteomics based on protein purification and chemical labeling confirms this observation. Furthermore, obvious associations between the two intact glycopeptides (EEQFN 177STYR (H3N4) of IgG4, EEQYN 227STFR (H3N4F1) of IgG3) and response to treatment are observed, which may play a guiding role in cancer immunotherapy. Our findings could benefit future clinical disease management.

Comprehensive Glycomic and Glycoproteomic Analyses of Human Programmed Cell Death Protein 1 Extracellular Domain

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity

Expression and Purification of Soluble Human Programmed Death-1 in Escherichia Coli.

N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

N-glycosylation of PD-1 promotes binding of camrelizumab

Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1

Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1

Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker

Identification of a Monoclonal Antibody That Targets PD-1 in a Manner Requiring PD-1 Asn58 Glycosylation

Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy

Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells

Identification and Functional Characterization of Glycosylation of Recombinant Human Platelet- Derived Growth Factor-Bb in Pichia Pastoris

Recent Findings in the Posttranslational Modifications of PD-L1

Amplified visualization and function exploration of exosomal protein-specific glycosylation using hybridization chain reaction from non-functional epitope

Research Progress of PD‐L1 Non‐glycosylation in Cancer Immunotherapy

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

Discovery of Peptide Inhibitors Targeting Human Programmed Death 1 (PD-1) Receptor.